• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    T

    Thrombosis Research Institute

    EST. 2003
    863论文总数
    5.3万引用总数

    论文量&引用量时间轴

    机构学者

    论文(863)

    年份
    起
    –
    止
    排序
    1Tumour-Associated MUC1 Exerts Multiple Effects on Cholesterol and Lipid Metabolism-A Potential Pathogenic Effector of Atherosclerosis in Cancer.
    Yunliang Chen,Michael Scully

    (1) Cancer has been shown to contribute to the progression of atherosclerosis, while inflammatory aspects of atherosclerosis can exert profound effects on cancer development and outcomes. TA-MUC1 (Tumour-associated Mucin 1) is a transmembrane glycoprotein that is overexpressed in many human epithelial cancers lining the intestine. Interestingly, the lack of intestinal MUC1 has been shown to impair cholesterol uptake in MUC1-/- mice. (2) To investigate whether TA-MUC1 could have specific effects on cholesterol metabolism and, thereby, have the potential of impacting the pathogenesis of atherosclerosis in cancer patients. (3) The effect of TA-MUC1 on cholesterol and lipid metabolism was assayed using MUC1 gene knock down breast cancer cells. An in vitro coculturing model similar to in vivo biological conditions was used to determine that TA-MUC1 could also modulate the cholesterol metabolism of other cells. (4) Reduction or inhibition of TA-MUC1 activity resulted in a significant alteration in a number of the signalling pathways and proteins that are relevant to abnormal cholesterol metabolism (p < 0.0001). Coculturing of TA-MUC1 cancer cells with THP-1 cells also notably effectively induced monocytic THP-1 cell differentiation towards foam cells-foam cells being a characteristic feature of atherosclerotic blood vessels. (5) Previously, we found TA-MUC1 downregulation led to a reduction in procoagulant and prothrombotic properties of the cancer cells as well as modulation of the aberrant calcium signalling pathways of cancer cells. Taken together with these current results, this suggests that TA-MUC1 in cancer cells has multiple effects on cholesterol and lipid metabolism, which also impacts other cells in the cellular bioenvironment. TA-MUC1 could thereby act as an important pathogenic effector of atherosclerosis in cancer. These results can also be considered in respect of the therapeutic anti-MUC1 antibody, which was able to reduce the effect of TA-MUC1 on cholesterol metabolism. Modulation of cholesterol metabolism via targeting TA-MUC1 could, therefore, be of great benefit to cancer patients with atherosclerosis.

    2026International journal of molecular sciences(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Histidine-rich Glycoprotein is Not Associated with Thrombosis in a UK Biobank Mendelian Randomisation Analysis
    Yuncheng Duan, Hamish M. Aitken-Buck,Peter MacCallum, Jeffrey I. Weitz,Ajay K. Kakkar,Andrew S. Allen

    ABSTRACT Background Histidine-rich glycoprotein (HRG) is a regulator of coagulation that has been linked to experimental thrombosis, but its causal role in human thrombotic disease remains unclear. Objectives To determine whether HRG has a role in thrombosis, we evaluated the association between genetically determined HRG variation and thrombosis risk using Mendelian randomisation (MR). Methods We performed a two-sample MR analysis in UK Biobank using non-overlapping samples. Separate genome-wide association studies (GWAS) were conducted to identify single-nucleotide polymorphisms (SNPs) associated with circulating HRG protein levels and to estimate SNP associations with thrombosis outcomes. Genetic instruments were derived from the HRG GWAS measurements and applied to assess associations with overall, venous, and arterial thrombosis. Sensitivity analyses using multiple MR methods were undertaken, alongside adjusted logistic regression models in participants with measured HRG levels. Results Among 30,680 participants with HRG measurements, GWAS identified multiple loci associated with HRG levels, with the strongest signal at the rs9898 SNP (β=0.52; P=1.1×10 −306 ). Single instrument MR found no association between HRG protein levels predicted by the rs9898 SNP and risk of overall thrombosis (β=−0.00660; P=0.622), venous thrombosis (β=0.0101; P=0.650) and arterial thrombosis (β=−0.0137; P=0.384). Similar null findings were observed using multi-instrument MR approaches. In complementary analyses, measured HRG levels were not associated with thrombosis after adjustment for age, sex, and C-reactive protein, and results were unchanged after stratification by rs9898 genotype. Conclusion Genetically determined variation in HRG is not associated with thrombotic risk, indicating that HRG-related coagulation phenotypes do not translate into clinically meaningful thrombosis.

    2026
    引用
    AI阅读
    加入学术空间
    3Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
    C Michael Gibson,P Gabriel Steg,M Cecilia Bahit,Rasha Al-Lamee,Shamir R Mehta,Roxana Mehran,Jeffrey I Weitz,Shinya Goto,Jose Carlos Nicolau,Renato D Lopes,Junbo Ge,Nebojsa Tasic,

    BACKGROUND:Patients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. METHODS:In this phase 3, randomized, placebo-controlled trial, we evaluated the efficacy and safety of milvexian when added to standard antiplatelet therapy within 7 days after an acute coronary syndrome event. Patients were assigned in a 1:1 ratio to receive oral milvexian (25 mg twice daily) or matched placebo. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or ischemic stroke as evaluated in a time-to-event analysis. The principal safety outcome was Bleeding Academic Research Consortium (BARC) type 3c or 5 bleeding (intracranial or intraocular bleeding that compromises vision or fatal bleeding). RESULTS:After a planned interim analysis that was based on 556 adjudicated efficacy end points, the trial was terminated for futility. A total of 14,194 patients had been enrolled, with 7094 assigned to receive milvexian and 7100 to receive placebo. After a median follow-up of 12.2 months, a primary efficacy outcome event had occurred in 384 patients (5.4%) in the milvexian group and in 365 patients (5.1%) in the placebo group (hazard ratio, 1.05; 95% confidence interval, 0.91 to 1.21; P = 0.50). BARC type 3c or 5 bleeding occurred in 23 patients (0.3%) in the milvexian group and in 22 patients (0.3%) in the placebo group (P = 0.88). CONCLUSIONS:Among patients with a recent acute coronary syndrome event, milvexian did not decrease the risk of cardiovascular death, myocardial infarction, or ischemic stroke but did not increase the risk of intracranial or fatal bleeding, as compared with placebo. (Funded by Janssen Research and Development and Bristol Myers Squibb; LIBREXIA ACS ClinicalTrials.gov number, NCT05754957.).

    2026The New England journal of medicine(2026)
    引用
    AI阅读
    加入学术空间
    4DOAC Score among Patients Receiving Vitamin K Antagonists.
    Rahul Aggarwal,Christian T Ruff,Michael G Palazzolo, Fionn Cléirigh Büttner,Karen Pieper,John Eikelboom,Manesh Patel,Christopher B Granger,Lars Wallentin,Ziad Hijazi,Saverio Virdone,Peter Zimetbaum,

    BACKGROUND:The direct acting oral anticoagulant (DOAC) score is a bleeding risk score that incorporates 10 common clinical variables to risk stratify major bleeding in patients with atrial fibrillation and demonstrated improved risk stratification compared with HAS-BLED in patients receiving DOACs. This study evaluates the discriminative performance of the DOAC score among patients taking vitamin K antagonists (VKAs). METHODS:Data were obtained from COMBINE-AF and GARFIELD-AF. COMBINE-AF included patients with atrial fibrillation randomized to warfarin from 4 clinical trials: RE-LY, ARISTOTLE, ROCKET-AF, and ENGAGE AF-TIMI 48. GARFIELD-AF included patients with atrial fibrillation prescribed VKAs in a registry. The DOAC score of each patient was determined, based on commonly obtained clinical variables. Patients were then stratified by DOAC score clinical risk categories (very low [score: 0-3], low [score: 4-5], moderate [score: 6-7], high [score: 8-9], and very high [score: 10]), and the rate of major bleeding at 1 year was compared between groups. Discrimination was assessed using C-statistics and compared with HAS-BLED using DeLong's test. RESULTS:A total of 28,818 patients in COMBINE-AF and 20,183 patients in GARFIELD-AF receiving vitamin K antagonists were included. Of these individuals, 994 (3.4%) in COMBINE-AF and 313 (1.6%) in GARFIELD-AF experienced a major bleeding event at 1 year. Patients in higher DOAC score risk categories experienced greater 1-year major bleeding rates in COMBINE-AF, including very low (1.8 events per 100 person-years [events/100p-y]), low (3.0 events/100 p-y), moderate (4.6 events/100 p-y), high (5.6 events/100 p-y), and very high (7.9 events/100 p-y). Discrimination in COMBINE-AF was moderate and higher than HAS-BLED at 1 year (C-statistic: 0.62 vs 0.59, P < .001). In GARFIELD-AF, higher risk categories also had higher 1-year major bleeding rates: very low (0.8 events per 100 person-years [events/100 p-y]), low (1.5 events/100 p-y), moderate (2.2 events/100 p-y), high (3.2 events/100 p-y), and very high (7.6 events/100 p-y). Discrimination in GARFIELD-AF was moderate and higher than the HAS-BLED score at 1 year (C-statistic: 0.65 vs 0.62, P < .001). CONCLUSION:In patients with atrial fibrillation taking VKAs, the DOAC score was able to risk stratify patients based on bleeding risk, had moderate discrimination, and out-performed the HAS-BLED score in both a pooled clinical trials cohort and a usual care registry.

    2026American heart journal(2026)
    引用
    AI阅读
    加入学术空间
    5Atrial Fibrillation Outcomes in Patients from Asia and Non-Asia Countries: Insights from GARFIELD-AF
    Chun-Yan Cheng, Tian-Yu Lian, Xi-Jie Zhu,Saverio Virdone,Kai Sun,John Camm, Xian-Mei Li,Shinya Goto,Karen Pieper,Gloria Kayani, Xian-Hong Fang,Zhi-Cheng Jing,

    Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial fibrillation (AF) have been sparsely investigated.Objective To provide a contemporary prospective comparison of outcomes for newly diagnosed patients with AF, between Asian and non-Asian regions.Methods Six Asian countries (China, Japan, India, Singapore, South Korea and Thailand) and 29 countries outside Asia participated in the Global Anticoagulant Registry in the FIELD-AF (GARFIELD-AF) study. Newly diagnosed patients with AF, enrolled between 2010 and 2016, were followed up for≥2 years. The outcome studies were all-cause, cardiovascular and non-cardiovascular mortality, non-haemorrhagic stroke/systemic embolism (SE), major bleeding. The association of geographical region with clinical outcomes (event rates per 100 person-years) were estimated using multivariable Cox models.Results 13 841/52 057 (26.6%) GARFIELD-AF participants were enrolled in Asia. Average age and prevalence of cardiovascular comorbidities were lower than in non-Asian countries and patients at high risk of stroke (ie, CHA2DS2-VASc≥2 excl. sex) were less frequently anticoagulated (60.1% vs 73.2%). Non-vitamin K oral anticoagulant (NOAC) was similar in both regions (∼28%), though Asian patients were more frequently underdosed. Both Asian and non-Asian patients who received NOAC at enrolment experienced lower all-cause mortality and non-haemorrhagic stroke/SE compared with patients on other treatments or none.All-cause mortality, non-cardiovascular mortality and major bleeding were less frequent in patients from Asia versus non-Asia (HR (95% CI): 0.62 (0.39 to 0.99), 0.52 (0.28 to 0.97), 0.58 (0.36 to 0.96), respectively). Associations of moderate-to-severe chronic kidney disease and vascular disease with increased risk of all-cause mortality were stronger in Asian versus non-Asian patients (interaction p values: 0.0250 and 0.0076, respectively). There was notable heterogeneity in oral anticoagulant (OAC) usage within the Asian countries.Conclusions Patients in Asian countries had a lower risk of all-cause mortality and major bleeding compared to the rest of the world. NOAC had evident benefits for reducing mortality and stroke across populations. Further studies on sociocultural impacts on OAC outcomes are needed.Trial registration number ClinicalTrials.gov NCT01090362.

    2025OPEN HEART(2025)引用:9
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 863 篇论文

    合作机构(100)

    麦克马斯特大学合作论文 119
    东海大学合作论文 67
    伦敦大学合作论文 66
    拜耳合作论文 41
    爱丁堡大学合作论文 41
    慕尼黑工业大学合作论文 40
    布莱根妇女医院合作论文 37
    玛希隆大学合作论文 32
    杜克大学合作论文 31
    哈佛大学合作论文 26

    机构统计